Apolipoprotein E: Essential catalyst of the Alzheimer amyloid cascade

International Journal of Alzheimer's Disease

Volumn , Issue , 2012, Pages

  Potter, Huntington ^a,b   Wisniewski, Thomas ^c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BINDING PROTEIN; CHAPERONE; CLUSTERIN; IBUPROFEN; KINESIN 5; LIVER X RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OLIGOMER;

ALLELE; ALZHEIMER DISEASE; AMYLOID PLAQUE; BIOCATALYST; GENETIC RISK; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHERITANCE; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW; RISK FACTOR;

EID: 84864949729     PISSN: None     EISSN: 20900252     Source Type: Journal    
DOI: 10.1155/2012/489428     Document Type: Review

References (91)

1. Hardy J., Alzheimer's disease: the amyloid cascade hypothesisan update and reappraisal Journal of Alzheimer's Disease 2006 9 3 151 153 (Pubitemid 44253307)
2. Karran E., Mercken M., De Strooper B., The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics Nature Reviews Drug Discovery 2011 10 698 712
3. Walsh D. M., Lomakin A., Benedek G. B., Condron M. M., Teplow D. B., Amyloid -protein fibrillogenesis: detection of a protofibrillar intermediate Journal of Biological Chemistry 1997 272 35 22364 22372 (Pubitemid 27382873)
4. Lambert M. P., Barlow A. K., Chromy B. A., Edwards C., Freed R., Liosatos M., Morgan T. E., Rozovsky I., Trommer B., Viola K. L., Wals P., Zhang C., Finch C. E., Krafft G. A., Klein W. L., Diffusible, nonfibrillar ligands derived from A 1-42 are potent central nervous system neurotoxins Proceedings of the National Academy of Sciences of the United States of America 1998 95 11 6448 6453
5. Podlisny M. B., Walsh D. M., Amarante P., Ostaszewski B. L., Stimson E. R., Maggio J. E., Teplow D. B., Selkoe D. J., Oligomerization of endogenous and synthetic amyloid -protein at nanomolar levels in cell culture and stabilization of monomer by Congo red Biochemistry 1998 37 11 3602 3611 (Pubitemid 28162915)
6. Lesné S., Ming T. K., Kotilinek L., Kayed R., Glabe C. G., Yang A., Gallagher M., Ashe K. H., A specific amyloid- protein assembly in the brain impairs memory Nature 2006 440 7082 352 357
7. Wang H. W., Pasternak J. F., Kuo H., Ristic H., Lambert M. P., Chromy B., Viola K. L., Klein W. L., Stine W. B., Krafft G. A., Trommer B. L., Soluble oligomers of amyloid (142) inhibit long-term potentiation but not long-term depression in rat dentate gyrus Brain Research 2002 924 2 133 140 (Pubitemid 34102301)
8. Walsh D. M., Klyubin I., Fadeeva J. V., Cullen W. K., Anwyl R., Wolfe M. S., Rowan M. J., Selkoe D. J., Naturally secreted oligomers of amyloid protein potently inhibit hippocampal long-term potentiation in vivo Nature 2002 416 6880 535 539 (Pubitemid 34288854)
9. Abraham C. R., Selkoe D. J., Potter H., Immunochemical identification of the serine protease inhibitor 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease Cell 1988 52 4 487 501 (Pubitemid 18067514)
10. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K., Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease Brain Research 1991 541 1 163 166
11. Wisniewski T., Frangione B., Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid Neuroscience Letters 1992 135 2 235 238
12. Wisniewski T., Lalowski M., Golabek A., Vogel T., Frangione B., Is Alzheimer's disease an apolipoprotein E amyloidosis? The Lancet 1995 345 8955 956 958
13. Nilsson L., Rogers J., Potter H., The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease Frontiers in Bioscience 1998 3 d436 d446
14. Potter H., Wefes I. M., Nilsson L. N. G., The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation Neurobiology of Aging 2001 22 6 923 930 (Pubitemid 34066560)
15. Rozemuller A. J. M., van Gool W. A., Eikelenboom P., The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications Current Drug Targets 2005 4 3 223 233 (Pubitemid 40754159)
16. Alzheimer A., Uber eine eigenartige Erkrankung der Hirnride Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 1907 64 146 148
17. Rogers J., Luber-Narod J., Styren S. D., Civin W. H., Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease Neurobiology of Aging 1988 9 4 339 349 (Pubitemid 19262065)
18. Griffin W. S. T., Stanley L. C., Ling C., White L., MacLeod V., Perrot L. J., White C. L., Araoz C., Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America 1989 86 19 7611 7615 (Pubitemid 19254506)
19. Strittmatter W. J., Saunders A. M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G. S., Roses A. D., Apolipoprotein E: high-avidity binding to -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease Proceedings of the National Academy of Sciences of the United States of America 1993 90 5 1977 1981 (Pubitemid 23069980)
20. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families Science 1993 261 5123 921 923 (Pubitemid 23275809)
21. Strittmatter W. J., Roses A. D., Apolipoprotein E and Alzheimers disease Proceedings of the National Academy of Sciences of the United States of America 1995 92 4725 4727
22. Rubinsztein D. C., Hon J., Stevens F., Pyrah I., Tysoe C., Huppert F. A., Easton D. F., Holland A. J., Apo E genotypes and risk of dementia in Down syndrome American Journal of Medical Genetics 1999 88 344 347 (Pubitemid 29372246)
23. Mahley R. W., Huang Y., Weisgraber K. H., Detrimental effects of apolipoprotein E4: potential therapeutic targets in Alzheimer's disease Current Alzheimer Research 2007 4 5 537 540 (Pubitemid 350252972)
24. Kim J., Basak J. M., Holtzman D. M., The role of apolipoprotein E in Alzheimer's disease Neuron 2009 63 3 287 303
25. Verghese P. B., Castellano J. M., Holtzman D. M., Apolipoprotein E in Alzheimer's disease and other neurological disorders The Lancet Neurology 2011 10 3 241 252
26. Hauser P. S., Narayanaswami V., Ryan R. O., Apolipoprotein E: from lipid transport to neurobiology Progress in Lipid Research 2011 50 1 62 74
27. Ma J., Yee A., Brewer H. B., Das S., Potter H., Amyloid-associated proteins 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer -protein into filaments Nature 1994 372 6501 92 94
28. Wisniewski T., Castano E. M., Golabek A., Vogel T., Frangione B., Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro American Journal of Pathology 1994 145 5 1030 1035 (Pubitemid 24345650)
29. Sanan D. A., Weisgraber K. H., Russell S. J., Mahley R. W., Huang D., Saunders A., Schmechel D., Wisniewski T., Frangione B., Roses A. D., Strittmatter W. J., Apolipoprotein E associates with amyloid peptide of Alzheimer's disease to form novel monofibrils. Isoform ApoE4 associates more efficiently than ApoE3 Journal of Clinical Investigation 1994 94 2 860 869
30. Ma J., Brewer H. B. Jr., Potter H., Alzheimer A neurotoxicity: promotion by antichymotrypsin, ApoE4; inhibition by A -related peptides Neurobiology of Aging 1996 17 5 773 780 (Pubitemid 26348879)
31. Bales K. R., Verina T., Dodel R. C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E. M., Little S. P., Cummins D. J., Piccardo P., Ghetti B., Paul S. M., Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition Nature genetics 1997 17 3 263 264
32. Bales K. R., Verina T., Cummins D. J., Du Y., Dodel R. C., Saura J., Fishman C. E., Delong C. A., Piccardo P., Petegnief V., Ghetti B., Paul S. M., Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 1999 96 26 15233 15238 (Pubitemid 30019795)
33. Holtzman D. M., Fagan A. M., Mackey B., Tenkova T., Sartorius L., Paul S. M., Bales K., Ashe K. H., Irizarry M. C., Hyman B. T., Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model Annals of Neurology 2000 47 6 739 747 (Pubitemid 30390194)
34. Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S. M., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2000 97 6 2892 2897 (Pubitemid 30159268)
35. Mucke L., Yu G. Q., McConlogue L., Rockenstein E. M., Abraham C. R., Masliah E., Astroglial expression of human 1-antichymotrypsin enhances Alzheimer-like pathology in amyloid protein precursor transgenic mice American Journal of Pathology 2000 157 6 2003 2010
36. Nilsson L. N. G., Bales K. R., DiCarlo G., Gordon M. N., Morgan D., Paul S. M., Potter H., -1-Antichymotrypsin promotes -sheet amyloid plaque deposition in a transgenic mouse model of Alzheimer's disease Journal of Neuroscience 2001 21 5 1444 1451 (Pubitemid 32182186)
37. Potter H., Bondy S. C., Cambell A., Beyond beta proteinthe essential role of inflammation in Alzheimer Amyloid formation Inflammatory Events in Neurodegeneration 2001 Prominent Press
38. Nilsson L. N. G., Gografe S., Costa D. A., Hughes T., Dressler D., Potter H., Use of fused circulations to investigate the role of apolipoprotein E as amyloid catalyst and peripheral sink in Alzheimers disease. Technology and Innovation. In press
39. Manelli A. M., Bulfinch L. C., Sullivan P. M., LaDu M. J., A 42 neurotoxicity in primary co-cultures: effect of apoE isoform and A conformation Neurobiology of Aging 2007 28 8 1139 1147 (Pubitemid 46810054)
40. Jones P. B., Adams K. W., Rozkalne A., Spires-Jones T. L., Hshieh T. T., Hashimoto T., von Armin C. A. F., Mielke M., Bacskai B. J., Hyman B. T., Apolipoprotein E: isoform specific differences in tertiary structure and interaction with amyloid- in human Alzheimer brain PLoS ONE 2011 6 1
41. Koffie R. M., Hashimoto T., Tai H.-C., Kay K. R., Serrano-Pozo A., Joyner D., Hou S., Kopeikina K. J., Frosch M. P., Lee V. M., Holtzman D. M., Hyman B. T., Spires-Jones T. L., Apolipoprotein E4 effects in Alzheimer disease are mediated by synaptotoxic oligomeric amyloid-beta Brain 2012 135 2155 2168
42. Wisniewski T., Lalowski M., Golabek A., Vogel T., Frangione B., Is Alzheimer's disease an apolipoprotein E amyloidosis? The Lancet 1995 345 8955 956 958
43. Naslund J., Thyberg J., Tjernberg L. O., Wernstedt C., Karlstrom A. R., Bogdanovic N., Gandy S. E., Lannfelt L., Terenius L., Nordstedt C., Characterization of stable complexes involving apolipoprotein E and the amyloid peptide in Alzheimer's disease brain Neuron 1995 15 1 219 228
44. Golabek A. A., Soto C., Vogel T., Wisniewski T., The Interaction between apolipoprotein E and Alzheimer's amyloid -peptide is dependent on -peptide conformation Journal of Biological Chemistry 1996 271 18 10602 10606
45. Wahrle S. E., Holtzman D. M., Dawbarn D., Allen S. J., Apolipoprotein E, amyloid beta-peptide and Alzheimer's disease Neurobiology of Alzheimer's Disease 2007 Oxford University Press 161 172
46. Castellano J. M., Kim J., Stewart F. R., Jiang H., DeMattos R. B., Patterson B. W., Fagan A. M., Morris J. C., Mawuenyega K. G., Cruchaga C., Goate A. M., Bales K. R., Paul S. M., Bateman R. J., Holtzman D. M., Human apoE isoforms differentially regulate brain amyloid- peptide clearance Science Translational Medicine 2011 3 89
47. Holtzman D. M., Bales K. R., Wu S., Bhat P., Parsadanian M., Fagan A. M., Chang L. K., Sun Y., Paul S. M., Expression of human apolipoprotein E reduces amyloid- deposition in a mouse model of Alzheimer's disease Journal of Clinical Investigation 1999 103 6 R15 R21
48. Fagan A. M., Watson M., Parsadanian M., Bales K. R., Paul S. M., Holtzman D. M., Human and murine apoE markedly alters A metabolism before and after plaque formation in a mouse model of Alzheimer's Disease Neurobiology of Disease 2002 9 3 305 318 (Pubitemid 34442079)
49. Dodart J. C., Marr R. A., Koistinaho M., Gregersen B. M., Malkani S., Verma I. M., Paul S. M., Gene delivery of human apolipoprotein E alters brain A burden in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2005 102 4 1211 1216 (Pubitemid 40170751)
50. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M. B., Holtzman D. M., Zlokovic B. V., apoE isoform-specific disruption of amyloid peptide clearance from mouse brain Journal of Clinical Investigation 2008 118 12 4002 4013
51. DeMattos R. B., Bales K. R., Cummins D. J., Dodart J. C., Paul S. M., Holtzman D. M., Peripheral anti-A antibody alters CNS and plasma A clearance and decreases brain A burden in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2001 98 15 8850 8855 (Pubitemid 32678116)
52. Dodart J. C., Bales K. R., Gannon K. S., Greene S. J., DeMattos R. B., Mathis C., DeLong C. A., Wu S., Wu X., Holtzman D. M., Paul S. M., Immunization reverses memory deficits without reducing brain A burden in Alzheimer's disease model Nature Neuroscience 2002 5 5 452 457 (Pubitemid 34454251)
53. DeMattos R. B., Bales K. R., Cummins D. J., Paul S. M., Holtzman D. M., Brain to plasma amyloid- efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease Science 2002 295 5563 2264 2267 (Pubitemid 34258840)
54. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., Duff K., Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to -amyloid Journal of Neuroscience 2003 23 1 29 33 (Pubitemid 36050401)
55. Jiang Q., Lee C. Y. D., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T. M., Collins J. L., Richardson J. C., Smith J. D., Comery T. A., Riddell D., Holtzman D. M., Tontonoz P., Landreth G. E., ApoE promotes the proteolytic degradation of A Neuron 2008 58 5 681 693 (Pubitemid 351778466)
56. Donkin J. J., Stukas S., Hirsch-Reinshagen V., Namjoshi D., Wilkinson A., May S., Chan J., Fan J., Collins J., Wellington C. L., ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice Journal of Biological Chemistry 2010 285 44 34144 34154
57. Cramer P. E., Cirrito J. R., Wesson D. W., Lee C. Y., Karlo J. C., Zinn A. E., Casali B.T., Restivo J. L., Goebel W. D., James M. J., Brunden K. R., Wilson D. A., Landreth G. E., ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models Science 2012 335 6075 1503 1506
58. Wahrle S. E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C. L., Bales K. R., Paul S. M., Holtzman D. M., Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease Journal of Clinical Investigation 2008 118 2 671 682 (Pubitemid 351206556)
59. Kim J., Jiang H., Park S., Eltorai A. E., Stewart F. R., Yoon H., Basak J. M., Finn M. B., Holtzman D. M., Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid- amyloidosis The Journal of Neuroscience 2011 31 18007 18012
60. Bien-Ly N., Gillespie A. K., Walker D., Yuon S. Y., Huang Y., Reducing human apolipoprotein E levels attenuates age dependent A accumulation in mutant human amyloid precursor protein transgenic mice The Journal of Neuroscience 2012 32 14 4803 4811
61. LaDu M. J., Falduto M. T., Manelli A. M., Reardon C. A., Getz G. S., Frail D. E., Isoform-specific binding of apolipoprotein E to -amyloid Journal of Biological Chemistry 1994 269 38 23403 23406
62. Aleshkov S., Abraham C. R., Zannis V. I., Interaction of nascent apoe2, apoe3, and apoe4 isoforms expressed in mammalian cells with amyloid peptide (140). Relevance to Alzheimer's disease Biochemistry 1997 36 34 10571 10580 (Pubitemid 27374151)
63. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J. D., Ladu M. J., Rostagno A., Frangione B., Ghiso J., Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid peptides Biochemical Journal 2000 348 2 359 365 (Pubitemid 30345209)
64. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H. W., Spijkers P., Guo H., Song X., Lenting P. J., Van Nostrand W. E., Zlokovic B. V., LRP/amyloid -peptide interaction mediates differential brain efflux of A isoforms Neuron 2004 43 3 333 344 (Pubitemid 39061126)
65. Dressler D., Potter H., Discovering Enzymes 1991 New York, NY, USA Scientific American Library, W. H. Freeman
66. Fersht A., Structure and Mechanism in Protein Science: A Guide to Enzyme Catalysis and Protein Folding 1999 New York, NY, USA W. H. Freeman
67. Herber D. L., Roth L. M., Wilson D., Wilson N., Mason J. E., Morgan D., Gordon M. N., Time-dependent reduction in A levels after intracranial LPS administration in APP transgenic mice Experimental Neurology 2004 190 1 245 253 (Pubitemid 39335723)
68. Herber D. L., Mercer M., Roth L. M., Symmonds K., Maloney J., Wilson N., Freeman M. J., Morgan D., Gordon M. N., Microglial activation is required for A clearance after intracranial injection of lipopolysaccharide in APP transgenic mice Journal of Neuroimmune Pharmacology 2007 2 2 222 231
69. Boyd T. D., Bennett S. P., Mori T., Governatori N., Runfeldt M., Norden M., Padmanabhan J., Neame P., Wefes I., Sanchez-Ramos J., Arendash G. W., Potter H., GM-CSF upregulated in rheumatoid arthritis reverses cognitive impairment and amyloidosis in Alzheimer mice Journal of Alzheimer's Disease 2010 21 2 507 518
70. Qiao X., Cummins D. J., Paul S. M., Neuroinflammation-induced acceleration of amyloid deposition in the APPV717F transgenic mouse European Journal of Neuroscience 2001 14 3 474 482 (Pubitemid 34203455)
71. Scholtzova H., Kascsak R. J., Bates K. A., Boutajangout A., Kerr D. J., Meeker H. C., Mehta P. D., Spinner D. S., Wisniewski T., Induction of toll-like receptor 9 signaling as a method for ameliorating alzheimer's disease-related pathology Journal of Neuroscience 2009 29 6 1846 1854
72. Hao J., Zhang W., Zhang P., Liu R., Liu L., Lei G., Su C., Miao J., Li Z., A 20-29 peptide blocking apoE/A interaction reduces full-length A 42/40 fibril formation and cytotoxicity in vitro Neuropeptides 2010 44 4 305 313
73. Liu Q., Wu W. H., Fang C. L., Li R. W., Liu P., Lei P., Hu J., Sun X., Zheng Y. Z., Zhao Y. F., Li Y. M., Mapping ApoE/Abeta binding regions to guide inhibitor discovery Molecular BioSystems 2011 7 1693 1700
74. Sadowski M., Pankiewicz J., Scholtzova H., Ripellino J. A., Li Y., Schmidt S. D., Mathews P. M., Fryer J. D., Holtzman D. M., Sigurdsson E. M., Wisniewski T., A synthetic peptide blocking the apolipoprotein E/ -amyloid binding mitigates -amyloid toxicity and fibril formation in vitro and reduces -amyloid plaques in transgenic mice American Journal of Pathology 2004 165 3 937 948 (Pubitemid 39129300)
75. Sadowski M. J., Pankiewicz J., Scholtzova H., Mehta P. D., Prelli F., Quartermain D., Wisniewski T., Blocking the apolipoprotein E/amyloid- interaction as a potential therapeutic approach for Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2006 103 49 18787 18792 (Pubitemid 44913488)
76. Yang J., Ji Y., Mehta P., Bates K. A., Sun Y., Wisniewski T., Blocking the apolipoprotein E/Amyloid- interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice Journal of Alzheimer's Disease 2011 24 2 269 285
77. Das S., Potter H., Expression of the Alzheimer amyloid-promoting factor antichymotrypsin is induced in human astrocytes by IL-1 Neuron 1995 14 2 447 456
78. Morihara T., Teter B., Yang F., Lim G. P., Boudinot S., Boudinot F. D., Frautschy S. A., Cole G. M., Ibuprofen suppresses interleukin-I induction of pro-amyloidogenic 1-antichymotrypsin to ameliorate -amyloid (a ) pathology in Alzheimer's models Neuropsychopharmacology 2005 30 6 1111 1120 (Pubitemid 40720969)
79. Ghiso J., Matsubara E., Koudinov A., Choi-Miura N. H., Tomita M., Wisniewski T., Frangione B., The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex Biochemical Journal 1993 293 1 27 30 (Pubitemid 23223142)
80. Koldamova R. P., Lefterov I. M., Lefterova M. I., Lazo J. S., Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A aggregation and toxicity Biochemistry 2001 40 12 3553 3560 (Pubitemid 32242812)
81. Paula-Lima A. C., Tricerri M. A., Brito-Moreira J., Bomfim T. R., Oliveira F. F., Magdesian M. H., Grinberg L. T., Panizzutti R., Ferreira S. T., Human apolipoprotein A-I binds amyloid- and prevents A -induced neurotoxicity International Journal of Biochemistry and Cell Biology 2009 41 6 1361 1370
82. Bell R. D., Sagare A. P., Friedman A. E., Bedi G. S., Holtzman D. M., Deane R., Zlokovic B. V., Transport pathways for clearance of human Alzheimer's amyloid -peptide and apolipoproteins E and J in the mouse central nervous system Journal of Cerebral Blood Flow and Metabolism 2007 27 5 909 918 (Pubitemid 46659038)
83. Ito S., Ohtsuki S., Kamiie J., Nezu Y., Terasaki T., Cerebral clearance of human amyloid- peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of low-density lipoprotein receptor-related protein-1 ligand complexes Journal of Neurochemistry 2007 103 6 2482 2490 (Pubitemid 350173573)
84. DeMattos R. B., O'dell M. A., Parsadanian M., Taylor J. W., Harmony J. A. K., Bales K. R., Paul S. M., Aronow B. J., Holtzman D. M., Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease Proceedings of the National Academy of Sciences of the United States of America 2002 99 16 10843 10848
85. Lemere C. A., Masliah E., Can Alzheimer disease be prevented by amyloid- immunotherapy? Nature Reviews Neurology 2010 6 2 108 119
86. Bacskai B. J., Kajdasz S. T., McLellan M. E., Games D., Seubert P., Schenk D., Hyman B. T., Non-Fc-mediated mechanisms are involved in clearance of amyloid- in vivo by immunotherapy Journal of Neuroscience 2002 22 18 7873 7878 (Pubitemid 35379092)
87. Borysov S. I., Granic A., Padmanabhan J., Walczak C. E., Potter H., Alzheimer A disrupts the mitotic spindle and directly inhibits mitotic microtubule motors Cell Cycle 2011 10 9 1397 1410
88. Takemura R., Nakata T., Okada Y., Yamazaki H., Zhang Z., Hirokawa N., mRNA expression of KIF1A, KIF1B, KIF2, KIF3A, KIF3B, KIF4, KIF5, and cytoplasmic dynein during axonal regeneration Journal of Neuroscience 1996 16 1 31 35 (Pubitemid 26010695)
89. Baas P. W., The role of motor proteins in establishing the microtubule arrays of axons and dendrites Journal of Chemical Neuroanatomy 1998 14 3-4 175 180 (Pubitemid 28362420)
90. Abisambra J. F., Fiorelli T., Padmanabhan J., Neame P., Wefes I., Potter H., LDLR expression and localization are altered in mouse and human cell culture models of Alzheimer's disease PLoS ONE 2010 5 1
91. Chen Y., Durakoglugil M. S., Xian X., Herz J., ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling Proceedings of the National Academy of Sciences of the United States of America 2010 107 26 12011 12016